“…[13] Although PDT is limited to evoking cellular damage,i th as found many applications in clinical therapies and it has inspired the development of medical light-delivery systems.Photopharmacology,w hich uses light to control distinct drugtarget interactions,might provide the possibility for moreselective treatments by taking advantage of the instrumentation and technology developed for PDT. [19] Currently,p hotopharmacology is at the stage of defining and evaluating the molecular targets,supported by the results of in vitro studies on receptor binding,enzyme inhibition, and general cellular toxicity.Important breakthroughs have been made in the fields of light-controlled cancer chemotherapy, [20][21][22][23][24] neurology, [25][26][27] diabetes, [28] and antimicrobial agents, [29] among others.F uture milestones on the way to clinically applied photopharmacology will, in our opinion, include in vivo testing and extensive toxicity studies.A lso of great importance will be the evaluation of photopharmacology through molecular imaging to study the distribution of the photoactivated drugs and confirm their localized action. Optogenetics is av aluable photophysiological tool that relies on using light to modulate the activity of genetically engineered ion channels,w hich are usually derived from photoresponsive rhodopsins (Figure 1c).…”